16.15
+0.24(+1.51%)
Currency In USD
Address
Paasheuvelweg 25a
Amsterdam, 1105 BP
Netherlands
Phone
31 20 240 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
480
First IPO Date
February 05, 2014
| Name | Title | Pay | Year Born |
| Mr. Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | 575,462 | 1973 |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary | 635,561 | 1962 |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer | 732,169 | 1969 |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 0 | N/A |
| Eileen Sawyer | Vice President of Global Medical Affairs | 0 | N/A |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director | 0 | N/A |
| Ms. Erin Boyer | Chief People & Culture Officer | 0 | N/A |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer | 0 | 1965 |
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations | 0 | N/A |
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.